Clinical trial

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

NCT00415246

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2006-11-01

PhasePHASE3

Study timeline

Study start (unknown)2006-11-01Date precision: month

Registry last updated2019-11-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)DRUG

Sponsors & collaborators

Ipsenlead sponsor

Mapped research locations

ParisFrance4 BrusselsBelgium3 RigaLatvia2 MadridSpain1 WarsawPoland1 ToulouseFrance1 MarseilleFrance1 LyonFrance1 LilleFrance1 LeuvenBelgium1 NantesFrance1 RennesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00415246 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.